706 related articles for article (PubMed ID: 22425824)
21. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
22. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
23. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Nicasio AM; Eagye KJ; Nicolau DP; Shore E; Palter M; Pepe J; Kuti JL
J Crit Care; 2010 Mar; 25(1):69-77. PubMed ID: 19427167
[TBL] [Abstract][Full Text] [Related]
25. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
Friedland I; Gallagher G; King T; Woods GL
J Chemother; 2004 Oct; 16(5):437-41. PubMed ID: 15565908
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and antibiotic susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae in Estonian intensive care units in comparison with European data.
Lõivukene K; Sepp E; Adamson V; Mitt P; Kallandi U; Otter K; Naaber P
Scand J Infect Dis; 2006; 38(11-12):1001-8. PubMed ID: 17148068
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
Crandon JL; Kuti JL; Jones RN; Nicolau DP
Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582
[TBL] [Abstract][Full Text] [Related]
30. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
31. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
33. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
34. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
35. Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients.
Varaiya A; Kulkarni N; Kulkarni M; Bhalekar P; Dogra J
Indian J Med Res; 2008 Apr; 127(4):398-402. PubMed ID: 18577797
[TBL] [Abstract][Full Text] [Related]
36. A Combination Antibiogram Evaluation for
Puzniak L; DePestel DD; Srinivasan A; Ye G; Murray J; Merchant S; DeRyke CA; Gupta V
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917987
[No Abstract] [Full Text] [Related]
37. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Hagihara M; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
[TBL] [Abstract][Full Text] [Related]
38. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.
Zelenitsky SA; Ariano RE; Zhanel GG
J Antimicrob Chemother; 2011 Feb; 66(2):343-9. PubMed ID: 20926397
[TBL] [Abstract][Full Text] [Related]
40. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting.
Juan C; Gutiérrez O; Oliver A; Ayestarán JI; Borrell N; Pérez JL
Clin Microbiol Infect; 2005 Nov; 11(11):887-92. PubMed ID: 16216103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
